935 completed, 115 terminated, 73 active not recruiting, 64 recruiting. 1244 Phase 1, 143 Phase 2.
Follow AstraZeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | AstraZeneca | 92 | 2026-10-30 | 2026-07-07 |
| A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954 [14C]AZD4954 Oral Solution, AZD4954 film-coated tablet, [14C]AZD4954 Solution for Infusion - Healthy Participants | Phase 1 | Not yet recruiting | AstraZeneca | 16 | 2026-10-19 | 2026-09-10 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| Study of Safety and PK of AZD0543 in Healthy Adults AZD0543, Placebo - Human Metapneumovirus Infection | Phase 1 | Recruiting | AstraZeneca | 144 | 2026-08-31 | 2026-09-17 |
| A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144 AZD4144 - Hepatic Impairment | Phase 1 | Not yet recruiting | AstraZeneca | 30 | 2026-08-24 | 2026-08-24 |
| Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin Balcinrenone/dapagliflozin - Kidney Failure | Phase 1 | Completed | AstraZeneca | 10 | 2026-08-06 | 2026-10-20 |
| Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants AZD4144, Itraconazole - Healthy | Phase 1 | Recruiting | AstraZeneca | 32 | 2026-07-30 | 2026-09-28 |
| A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B - Healthy Participants | Phase 1 | Recruiting | AstraZeneca | 152 | 2026-07-27 | 2026-09-16 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers AZD4916, Placebo - Healthy Participants | Phase 1 | Recruiting | AstraZeneca | 160 | 2026-07-23 | 2026-09-28 |
| A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2 - RSV Respiratory Syncytial Virus | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 164 | 2026-07-08 | 2026-10-29 |
| Human ADME Study of [14C]-AZD1390 AZD1390 - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | AstraZeneca | 8 | 2026-06-30 | 2026-06-12 |
| A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults AZD7760, Placebo - Staphylococcus Aureus Bloodstream Infection | Phase 1 | Active not recruiting | AstraZeneca | 18 | 2026-06-29 | 2026-10-06 |
| A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP - Healthy Participants | Phase 1 | Completed | AstraZeneca | 18 | 2026-06-10 | 2026-09-28 |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 152 | 2026-06-03 | 2026-10-14 |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer AZD8359 - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 42 | 2026-05-18 | 2026-10-09 |
| A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants Elecoglipron, Atorvastatin, Rosuvastatin - Healthy Participants | Phase 1 | Active not recruiting | AstraZeneca | 48 | 2026-04-16 | 2026-08-28 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults AZD4954, Laroprovstat - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2026-04-10 | 2026-08-04 |
| A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab SC durvalumab + rHu, IV durvalumab, Tremelimumab - Solid Tumours | Phase 1 | Recruiting | AstraZeneca | 40 | 2026-03-31 | 2026-09-24 |
Showing 20 of 1244. Sign in to see all of them.
Diabetes Mellitus, Type 2 (83) · Neoplasms (73) · Carcinoma, Non-Small-Cell Lung (71) · Breast Neoplasms (54) · Asthma (38) · Neoplasm Metastasis (33) · Pulmonary Disease, Chronic Obstructive (33) · Ovarian Neoplasms (31) · Prostatic Neoplasms (25) · Colorectal Neoplasms (23) · Obesity (23) · Renal Insufficiency (22) · Squamous Cell Carcinoma of Head and Neck (20) · Arthritis, Rheumatoid (19) · Diabetes Mellitus (19)
durvalumab (102) · olaparib (53) · tremelimumab (43) · AZD 6244 (38) · dapagliflozin (38) · Carboplatin (30) · Paclitaxel (29) · Cisplatin (26) · Rosuvastatin Calcium (26) · Gefitinib (23) · Metformin (22) · cediranib (21) · AZD1656 (20) · Gemcitabine (20) · Itraconazole (20)
United States (580) · United Kingdom (330) · Japan (134) · Germany (104) · Sweden (86) · Spain (82) · South Korea (75) · France (73) · Canada (62) · China (62) · Australia (56) · Netherlands (50) · Taiwan (42) · Italy (38) · Belgium (34)
Mark Sostek, MD (13) · Bo Fransson, MD (10) · Mirjana Kujacic (10) · David Mathews, MD (9) · Helen Lunde, MD (9) · Ronald Goldwater, MD (9) · David Han, MD (8) · Aslak Rautio (7) · Darren Wilbraham, MBBS, DCPSA (7) · Rainard Fuhr, Dr. med. (7)
PMID 29856004, PMID 24408516, PMID 34904813, PMID 21819160, PMID 22726593, PMID 22943931, PMID 23549864, PMID 23922302, PMID 24669829, PMID 24677117, PMID 26519231, PMID 26933507, PMID 26961146, PMID 27745744, PMID 27875488, PMID 28013354, PMID 28985960, PMID 29178442, PMID 29381826, PMID 30171779, PMID 31500595, PMID 32907575, PMID 34473343, PMID 35227647, PMID 38231777, PMID 38258274, PMID 38504437, PMID 39798707, PMID 41677208, PMID 42802645, PMID 19393840, PMID 19553641, PMID 19706990, PMID 20678684, PMID 21035955, PMID 21170669, PMID 21171670, PMID 21226818, PMID 21410733, PMID 21414193, PMID 21477416, PMID 21494838, PMID 21631929, PMID 21960668, PMID 21976672, PMID 22078153, PMID 22145984, PMID 22168538, PMID 22248721, PMID 22293660
2023 (26), 2015 (17), 2008 (12), 2014 (11), 2017 (11), 2018 (11), 2025 (11), 2009 (8), 2016 (7), 2019 (5), P30CA015704 (2), 2005 (1), R01CA136551 (1), UG3DA054825 (1), UG3TR002445 (1)